Vinten Martin, Larsen Michael, Lund-Andersen Henrik, Sander Birgit, La Cour Morten
Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark.
Acta Ophthalmol Scand. 2007 Feb;85(1):21-6. doi: 10.1111/j.1600-0420.2006.00806.x.
To assess retinal vascular permeability and vessel diameter changes after intravitreal triamcinolone acetonide (IVTA) injection in eyes with persistent foveal thickening after photocoagulation for diabetic macular oedema (DMO).
We calculated the blood-retinal barrier permeability as measured by vitreous fluorophotometry, artery and venous vessel diameter at the temporal vascular arcades as measured on digital fundus photos, and retinal thickness as measured by optical coherence tomography. Seven patients with type 2 diabetes and DMO were examined immediately before and 1 week after IVTA 2 mg. The study was designed as an open-label interventional case series using the fellow eyes as untreated controls.
One week after IVTA, we observed that, compared with baseline values, blood-retinal barrier permeability had decreased to 27.2 +/- 3.6% (p < 0.0001), retinal artery diameter had decreased to 94.9 +/- 0.02% (p = 0.05), retinal vein diameter had decreased to 89.2 +/- 0.03% (p = 0.02) and foveal thickness had decreased to 68.7 +/- 6.9% (p = 0.004). Visual acuity (VA) improved by 7.4 +/- 2.2 letters (p = 0.01). No significant change was observed in control eyes except that mean VA deteriorated by 2.6 +/- 0.9 letters (p = 0.03). Changes in permeability were closely correlated to changes in retinal thickness (R = 0.84) and venoule diameter (R = 0.93) in treated eyes.
Intravitreal injection of triamcinolone acetonide in eyes with DMO is followed by a marked reduction in retinal vascular leakage and a concomitant reduction in retinal vessel calibre.
评估糖尿病性黄斑水肿(DMO)光凝治疗后持续性黄斑中心凹增厚的眼中玻璃体内注射曲安奈德(IVTA)后视网膜血管通透性和血管直径的变化。
我们通过玻璃体荧光光度法计算血视网膜屏障通透性,通过数字眼底照片测量颞侧血管弓处的动脉和静脉血管直径,并通过光学相干断层扫描测量视网膜厚度。7例2型糖尿病合并DMO患者在注射2mg IVTA前及注射后1周接受检查。本研究设计为开放标签干预性病例系列,以对侧眼作为未治疗对照。
IVTA注射1周后,我们观察到,与基线值相比,血视网膜屏障通透性降至27.2±3.6%(p<0.0001),视网膜动脉直径降至94.9±0.02%(p=0.05),视网膜静脉直径降至89.2±0.03%(p=0.02),黄斑中心凹厚度降至68.7±6.9%(p=0.004)。视力(VA)提高了7.4±2.2个字母(p=0.01)。对照眼中未观察到显著变化,只是平均视力下降了2.6±0.9个字母(p=0.03)。治疗眼中通透性的变化与视网膜厚度(R=0.84)和静脉直径(R=0.93)的变化密切相关。
DMO患者玻璃体内注射曲安奈德后,视网膜血管渗漏明显减少,同时视网膜血管管径减小。